These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24065086)

  • 21. Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway.
    Sui Y; Zheng X; Zhao D
    Tumour Biol; 2015 Nov; 36(11):8661-70. PubMed ID: 26044564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
    Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
    Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
    Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
    Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Kim SH; Chung YH; Yang SH; Kim JA; Jang MK; Kim SE; Lee D; Lee SH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Suh DJ
    Korean J Hepatol; 2009 Sep; 15(3):320-30. PubMed ID: 19783881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC.
    Ding K; Fan L; Chen S; Wang Y; Yu H; Sun Y; Yu J; Wang L; Liu X; Liu Y
    Oncol Rep; 2015 Dec; 34(6):3297-303. PubMed ID: 26397192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma].
    Cui BK; Zhang CQ; Zhang Y; Yuan YF; Zhang YQ; Shi M; Chen MS; Li SP; Li JQ
    Ai Zheng; 2006 Jul; 25(7):876-9. PubMed ID: 16831281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin.
    Dong Q; Zhu X; Dai C; Zhang X; Gao X; Wei J; Sheng Y; Zheng Y; Yu J; Xie L; Qin Y; Qiao P; Zhou C; Yu X; Jia H; Ren N; Zhou H; Ye Q; Qin L
    Oncotarget; 2016 Mar; 7(11):12997-3012. PubMed ID: 26824421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of CENP-H as a novel prognostic biomarker for human hepatocellular carcinoma progression and patient survival.
    Lu G; Shan T; He S; Ren M; Zhu M; Hu Y; Lu X; Zhang D
    Oncol Rep; 2013 Nov; 30(5):2238-44. PubMed ID: 23970101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
    Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
    Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.
    Sieghart W; Losert D; Strommer S; Cejka D; Schmid K; Rasoul-Rockenschaub S; Bodingbauer M; Crevenna R; Monia BP; Peck-Radosavljevic M; Wacheck V
    J Hepatol; 2006 Jan; 44(1):151-7. PubMed ID: 16289418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Growth inhibition of human hepatocellular carcinoma by miRNA-204 via down-regulation of Bcl-2 and Sirt1 expression].
    Li K; Xyu Q; Liu X; Liu Q; Wang M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Feb; 31(2):168-72. PubMed ID: 25652855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The prognostic significance of preoperative plasma level of osteopontin in combination with intercellular adhesion molecule-1 for patients with hepatocellular carcinoma].
    Zhang H; Ren N; Ye QH; Sun HC; Wang L; Liu YK; Tang ZY; Qin LX
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):985-8. PubMed ID: 16194354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of osteopontin expression in human gastric carcinoma.
    Higashiyama M; Ito T; Tanaka E; Shimada Y
    Ann Surg Oncol; 2007 Dec; 14(12):3419-27. PubMed ID: 17896150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma.
    Peng SY; Ou YH; Chen WJ; Li HY; Liu SH; Pan HW; Lai PL; Jeng YM; Chen DC; Hsu HC
    Int J Oncol; 2005 Apr; 26(4):1053-61. PubMed ID: 15754002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
    Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
    Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of JWA promotes tumor invasion and predicts poor prognosis in human hepatocellular carcinoma.
    Wu X; Chen H; Gao Q; Bai J; Wang X; Zhou J; Qiu S; Xu Y; Shi Y; Wang X; Zhou J; Fan J
    Mol Carcinog; 2014 Apr; 53(4):325-36. PubMed ID: 23169062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
    Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
    Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
    Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
    Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The influence of downregulation of ezrin expression by RNA interference on the growth and metastasis of hepatocellular carcinoma: experiment in vitro].
    Zhang Y; Hu MY; Chen BH; Wang ZJ; Zha XL; Liu KD
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):530-5. PubMed ID: 16681881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
    Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
    Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.